Daptomycin therapy failure in an adolescent with methicillin-resistant staphylococcus aureus bacteremia

Research output: Contribution to journalArticlepeer-review

Abstract

Daptomycin is a Food and Drug Administration-approved alternative to vancomycin for the treatment of serious methicillin-resistant Staphylococcus aureus infections in adults. Treatment failure with daptomycin is increasingly reported in adults, but data in children are limited. We report an adolescent patient with severe burn injuries who had persistent methicillin-resistant Staphylococcus aureus bacteremia and rapidly developed nonsusceptibility to daptomycin. We review the relevant literature.

Original languageEnglish (US)
Pages (from-to)445-447
Number of pages3
JournalPediatric Infectious Disease Journal
Volume28
Issue number5
DOIs
StatePublished - May 2009

Keywords

  • Daptomycin
  • MRSA
  • Nonsusceptible
  • Resistance
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Daptomycin therapy failure in an adolescent with methicillin-resistant staphylococcus aureus bacteremia'. Together they form a unique fingerprint.

Cite this